Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Challenges in identifying predictive markers to ICIs in triple-negative breast cancer

Kevin Kalinsky • 22 Oct 2023
ESMO 2023
Breast Cancer Antibodies Pembrolizumab

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the challenges in identifying predictive markers of response to immune checkpoint inhibitors in triple-negative breast cancer (TNBC). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kevin Kalinsky

1:07
NeoTRIP: EFS in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk TNBC
Kevin Kalinsky • 22 Oct 2023
1:04
5-year monarchE results: abemaciclib + ET in high-risk EBC
Kevin Kalinsky • 22 Oct 2023
1:36
Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
Kevin Kalinsky • 22 Oct 2023
0:56
ESMO 2023: Key messages for breast cancer treatment
Kevin Kalinsky • 21 Oct 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals